Sort
82,697 grants matching “vaccine development”
Core 2 - Computational Biology Core
$792,549Rory Henderson · Duke University · U54 · FY2025 · AI
Novel delivery platform and antigen design for an effective COVID-19 vaccine
$792,476Suresh K Mittal · Purdue University · R01 · FY2020 · AI
Immunopharmacotherapy for Mitigating Opioid Addiction
$792,470Kim D Janda · Scripps Research Institute, The · UH2 · FY2015 · DA
Selecting HA glycosylation for improved vaccine responses
$792,434Joseph Zaia · Boston University Medical Campus · R01 · FY2023 · AI
Selecting HA glycosylation for improved vaccine responses
$792,434Joseph Zaia · Boston University Medical Campus · R01 · FY2022 · AI
Selecting HA glycosylation for improved vaccine responses
$792,434Joseph Zaia · Boston University Medical Campus · R01 · FY2024 · AI
Development of botulinum neurotoxin immunotherapy
$792,374James D. Marks · University Of California, San Francisco · U01 · FY2007 · AI
Human antibodies for therapeutic intervention of staph enterotoxin B exposure
$792,333Luigi Grasso · Morphotek, Inc. · U01 · FY2007 · AI
Transcriptomic Signatures of Influenza Vaccine Responses
$792,332Gregory A. Poland · Mayo Clinic Rochester · R01 · FY2020 · AI
Mechanisms of Enhanced Neutralizing Antibody Responses to Rhinovirus C
$792,076Yury A Bochkov · University Of Wisconsin-Madison · R01 · FY2021 · AI
New analytic approaches and endpoints in human HIV vaccine correlate studies
$792,039Margaret E Ackerman · Dartmouth College · R56 · FY2022 · AI
Developing recombinant coronavirus vaccines for SARS
$792,026Xuming Zhang · Univ Of Arkansas For Med Scis · U01 · FY2006 · AI
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
$791,948Jill Allison Hollenbach · University Of California, San Francisco · R01 · FY2023 · AI
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS
$791,912Theodora Hatziioannou · Rockefeller University · R01 · FY2017 · AI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
$791,766Athe M. Tsibris · Brigham And Women'S Hospital · R01 · FY2025 · AI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
$791,766Athe M. Tsibris · Brigham And Women'S Hospital · R01 · FY2023 · AI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
$791,766Athe M. Tsibris · Brigham And Women'S Hospital · R01 · FY2024 · AI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge
$791,764Peter Palese · Columbia University Health Sciences · U54 · FY2009 · AI
Influenza and Emerging Infectious Diseases
$791,726Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies
$791,681William Robert Jacobs · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · AI
Persistent Immunogenicity of IDLV delivering Gag and membrane tethered HIV-1 Envelope Trimers
$791,661Maria Blasi · Duke University · R01 · FY2025 · AI
traThe influence of rectal Chlamydia trachomatis infections on immunity and incident urogenital infections in women without an indication forrectal screening
$791,657Stephen J. Jordan · Indiana University Indianapolis · R01 · FY2025 · AI
Human Immune Monitoring Core
$791,601Holden T. Maecker · Stanford University · U19 · FY2011 · AI
Clinical Center-COPD Clinical Research Network
$791,575University Of Maryland Baltimore · U10 · FY2003 · HL
Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay
$791,483Ronald William Mink · Sedia Biosciences Corporation · R44 · FY2017 · AI